CanSino Biologics Inc. (6185.HK)
6185.HK Stock Price Chart
Explore CanSino Biologics Inc. interactive price chart. Choose custom timeframes to analyze 6185.HK price movements and trends.
6185.HK Company Profile
Discover essential business fundamentals and corporate details for CanSino Biologics Inc. (6185.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Mar 2019
Employees
1.11K
Website
https://www.cansinotech.comCEO
Xuefeng Yu
Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
6185.HK Financial Timeline
Browse a chronological timeline of CanSino Biologics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 20 Aug 2025
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $275.10M , missing expectations by -18.81%.
Earnings released on 29 Apr 2025
EPS came in at -$0.05 falling short of the estimated -$0.00 by -3.17K%, while revenue for the quarter reached $147.06M .
Earnings released on 27 Feb 2025
EPS came in at -$0.63 falling short of the estimated -$0.24 by -162.50%, while revenue for the quarter reached $297.08M , beating expectations by +0.09%.
Earnings released on 29 Oct 2024
EPS came in at $0.01 surpassing the estimated -$0.40 by +102.50%, while revenue for the quarter reached $291.74M , missing expectations by -25.66%.
Earnings released on 29 Aug 2024
EPS came in at -$0.22 surpassing the estimated -$0.37 by +40.54%, while revenue for the quarter reached $183.78M , missing expectations by -24.08%.
Earnings released on 29 Apr 2024
EPS came in at -$0.69 falling short of the estimated -$0.33 by -109.09%, while revenue for the quarter reached $123.64M , missing expectations by -50.23%.
Earnings released on 23 Feb 2024
EPS came in at -$1.88 falling short of the estimated -$0.49 by -283.67%, while revenue for the quarter reached $187.66M , missing expectations by -24.39%.
Earnings released on 30 Oct 2023
EPS came in at -$0.58 falling short of the estimated -$0.21 by -176.19%, while revenue for the quarter reached $165.76M , beating expectations by +30.17%.
Earnings released on 30 Aug 2023
EPS came in at -$2.84 falling short of the estimated -$0.01 by -35.40K%, while revenue for the quarter reached -$85.94M .
Earnings released on 28 Apr 2023
EPS came in at -$0.65 , while revenue for the quarter reached $114.78M .
Earnings released on 27 Feb 2023
EPS came in at -$1.78 falling short of the estimated $0.72 by -347.22%, while revenue for the quarter reached $368.60M , beating expectations by +149.29%.
Earnings released on 28 Oct 2022
EPS came in at -$2.12 falling short of the estimated $0.84 by -352.82%, while revenue for the quarter reached $85.25M , missing expectations by -76.50%.
Earnings released on 27 Aug 2022
EPS came in at -$0.53 falling short of the estimated $0.73 by -172.42%, while revenue for the quarter reached $152.70M , missing expectations by -79.39%.
Dividend declared on 13 Jul 2022
A dividend of $0.94 per share was announced, adjusted to $0.94. The dividend was paid on 19 Aug 2022.
Earnings released on 28 Apr 2022
EPS came in at $0.60 falling short of the estimated $0.73 by -17.26%, while revenue for the quarter reached $615.41M .
Earnings released on 26 Feb 2022
EPS came in at $2.31 surpassing the estimated $1.92 by +20.31%, while revenue for the quarter reached $1.49B , beating expectations by +0.63%.
Earnings released on 28 Oct 2021
EPS came in at $1.60 falling short of the estimated $2.87 by -44.25%, while revenue for the quarter reached $1.24B .
Earnings released on 28 Aug 2021
EPS came in at $3.85 falling short of the estimated $7.04 by -45.31%, while revenue for the quarter reached $1.91B .
Earnings released on 30 Apr 2021
EPS came in at -$0.06 , while revenue for the quarter reached $552.72M .
Earnings released on 26 Feb 2021
EPS came in at -$1.07 , while revenue for the quarter reached $22.82M .
Earnings released on 28 Oct 2020
EPS came in at -$0.36 , while revenue for the quarter reached $1.87M .
6185.HK Stock Performance
Access detailed 6185.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.